"Proprotein Convertases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteolytic enzymes that are involved in the conversion of protein precursors such as peptide prohormones into PEPTIDE HORMONES. Some are ENDOPEPTIDASES, some are EXOPEPTIDASES.
| Descriptor ID |
D043484
|
| MeSH Number(s) |
D08.811.277.656.837
|
| Concept/Terms |
Proprotein Convertases- Proprotein Convertases
- Convertases, Proprotein
- Proprotein Convertase
- Convertase, Proprotein
Prohormone Convertases- Prohormone Convertases
- Convertases, Prohormone
- Prohormone Convertase
- Convertase, Prohormone
Subtilisin-Like Proprotein Convertases- Subtilisin-Like Proprotein Convertases
- Convertases, Subtilisin-Like Proprotein
- Proprotein Convertases, Subtilisin-Like
- Subtilisin Like Proprotein Convertases
Pro-Opiomelanocortin Converting Enzyme- Pro-Opiomelanocortin Converting Enzyme
- Converting Enzyme, Pro-Opiomelanocortin
- Pro Opiomelanocortin Converting Enzyme
- POMC Enzyme
- POMC-Converting Enzyme
- POMC Converting Enzyme
- Pro-Opiocortin Converting Protease
- Converting Protease, Pro-Opiocortin
- Pro Opiocortin Converting Protease
- Proopiomelanocortin Convertase
- Convertase, Proopiomelanocortin
- POMC Convertase
- Convertase, POMC
- Pro-Opiocortin Converting Enzyme
- Converting Enzyme, Pro-Opiocortin
- Pro Opiocortin Converting Enzyme
|
Below are MeSH descriptors whose meaning is more general than "Proprotein Convertases".
Below are MeSH descriptors whose meaning is more specific than "Proprotein Convertases".
This graph shows the total number of publications written about "Proprotein Convertases" by people in this website by year, and whether "Proprotein Convertases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proprotein Convertases" by people in Profiles.
-
PCSK6 and Survival in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2023 06 01; 207(11):1515-1524.
-
PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all : Editorial to: "Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/Dl or Higher" by Henry N. Ginsberg et Al. Cardiovasc Drugs Ther. 2016 10; 30(5):427-431.
-
Precise regulation of the guidance receptor DMA-1 by KPC-1/Furin instructs dendritic branching decisions. Elife. 2016 Mar 14; 5.
-
The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance. Am J Respir Crit Care Med. 2015 Dec 01; 192(11):1275-86.
-
Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Curr Cardiol Rep. 2015 Nov; 17(11):104.
-
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015 Oct 27; 132(17):1648-66.
-
Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. J Biol Chem. 2015 Jul 24; 290(30):18609-20.
-
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 01; 36(17):1012-22.
-
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):331-40.
-
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):341-50.